

Supplementary Table 2: Event numbers and rates (per 100 person-years) of efficacy and safety endpoints < 30 days after procedure according to post-TAVR anticoagulant treatment.

	< 30 days after procedure											
	Monotherapy		DAPT		OAC mono		OAC duo		OAC triple		No anticoagulation	
	N events	Event rate	N events	Event rate	N events	Event rate	N events	Event rate	N events	Event rate	N events	Event rate
Ischemic stroke/SE	7	1.0	< 5	n.a.	5	1.6	8	2.0	< 5	n.a.	10	2.2
Mechanical complication by artificial heart valve	< 5	n.a.	< 5	n.a.	< 5	n.a.	< 5	n.a.	< 5	n.a.	< 5	n.a.
MACE	9	1.3	< 5	n.a.	6	2.0	9	2.2	< 5	n.a.	11	2.5
Combined bleeding endpoint (intracranial/extracranial/gastrointestinal bleeding)	12	1.8	< 5	n.a.	6	2.0	12	3.0	< 5	n.a.	9	2.0

DAPT, dual antiplatelet therapy; MACE, major adverse cardiac event; OAC, oral anticoagulation; SE, systemic embolism